Understanding Jadpro Live 2023 Standardizing Extended Endocrine Therapy Decision Making
Welcome to our comprehensive guide on Jadpro Live 2023 Standardizing Extended Endocrine Therapy Decision Making. Watch a panel discussion on strategies to avoid over- and under-treatment in HR+, early-stage breast cancer from the
Key Takeaways about Jadpro Live 2023 Standardizing Extended Endocrine Therapy Decision Making
- Factors to consider when treating patients with recurrent metastatic ER-positive/HER2-negative breast cancer and the rationale for ...
- Rob Iannone, Executive Vice President, Global Head of Research and Development and Chief Medical Officer, discusses the ...
- The Phase II/III ADAPT trial (NCT01779206) has previously revealed Ki67 and recurrence score in baseline core biopsy as ...
- How do you decide which adjuvant
- Theresa Wicklin Gillespie, PhD, MA, RN, FAAN, of the Winship Cancer Institute at Emory University, speaks about key takeaways ...
Detailed Analysis of Jadpro Live 2023 Standardizing Extended Endocrine Therapy Decision Making
Dr. VK Gadi, from the University of Illinois Cancer Center, highlights recent updates to national oncology practice guidelines ... Cynthia X. Ma, MD, PhD, professor of medicine, Washington University in Saint Louis, Missouri, discusses the challenges with ... Dr. Barbara Pistilli, MD moderates this session on adjuvant
In the second part of this series, the
In summary, understanding Jadpro Live 2023 Standardizing Extended Endocrine Therapy Decision Making gives us a better perspective.